Business
Further Positive Market Research Data for MED2002
Further Positive Market Research Data for MED2002.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 6261T Futura Medical PLC 16 October 2017 \n\n\n\n\n\nFor immediate release \n\n\n16 October 2017\n\n\n\n\n \n \n \n \n \nFutura Medical plc\n(\"Futura\" or \"the Company\")\n \nFurther Positive Market Research Data for MED2002\n \nFutura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that it has recently completed primary market research indicating that more than 60 per cent of physicians in the US consider that MED2002, the Company's novel gel for erectile dysfunction (\"ED\"), is an improvement over current ED therapies. \n \nThe research, carried out by leading healthcare strategy firm Cello Health Consulting (\"Cello\"), also revealed that at least 10 per cent of ED patients were contra-indicated to PDE5 inhibitors (such as Viagra® or Cialis®) because of their existing nitrate medication, a larger percentage than the 7.5 per cent historically stated by the Company based on previously conducted research.\n \nThe results of the survey are based on interviews with a total of 200 doctors in the US, Germany and France. To qualify for the interview each of the doctors had to been in general practice for at least five years and treated a minimum of 15 ED patients per month. Previously commissioned research by Futura into the potential size of both the prescription and over the counter (OTC) markets showed the significant commercial potential of the product. The Cello research was commissioned to gain insight into the attitudes of front line doctors who would be prescribing or recommending MED2002 to their patients - a crucial part of the sales process.\n \nOf the doctors interviewed, 64 per cent in the US, 60 per cent in Germany and 54 per cent in France considered that MED2002 is an improvement over current ED treatments, which are dominated by PDE5 inhibitors.\n \nThe results of the survey show that MED2002 could capture between a quarter and a third of the estimated ED patients in the US, including newly diagnosed and existing patients. The rapid speed of onset, of normally within five minutes, and the spontaneity associated with the use of the product were given by doctors as key reasons for expected patient use of the product. \n \nThe research focused on MED...